MEI Pharma Stock Forecast, Price & News

MEI Pharma (NASDAQ:MEIP) Frequently Asked Questions

Is MEI Pharma a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MEI Pharma stock.
View analyst ratings for MEI Pharma or view top-rated stocks.

How has MEI Pharma's stock been impacted by Coronavirus?

MEI Pharma's stock was trading at $1.55 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MEIP shares have increased by 117.4% and is now trading at $3.37.
View which stocks have been most impacted by COVID-19.

When is MEI Pharma's next earnings date?

MEI Pharma is scheduled to release its next quarterly earnings announcement on Thursday, February 3rd 2022.
View our earnings forecast for MEI Pharma.

How were MEI Pharma's earnings last quarter?

MEI Pharma, Inc. (NASDAQ:MEIP) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.13) earnings per share for the quarter, hitting the consensus estimate of ($0.13). The business had revenue of $13.39 million for the quarter, compared to the consensus estimate of $9.98 million. MEI Pharma had a negative net margin of 172.03% and a negative trailing twelve-month return on equity of 100.10%.
View MEI Pharma's earnings history.

What price target have analysts set for MEIP?

5 brokers have issued 12-month price targets for MEI Pharma's shares. Their forecasts range from $8.00 to $20.00. On average, they expect MEI Pharma's stock price to reach $11.00 in the next year. This suggests a possible upside of 226.4% from the stock's current price.
View analysts' price targets for MEI Pharma or view top-rated stocks among Wall Street analysts.

Who are MEI Pharma's key executives?

MEI Pharma's management team includes the following people:

• Daniel P. Gold, President, Chief Executive Officer & Director
• David M. Urso, Chief Operating Officer & General Counsel
• Brian G. Drazba, Chief Financial Officer & Secretary
• Richard G. Ghalie, Chief Medical Officer
• Tina C. Beamon, Chief Compliance Officer

Who are some of MEI Pharma's key competitors?

Some companies that are related to MEI Pharma include Rani Therapeutics (RANI), Amarin (AMRN), Madrigal Pharmaceuticals (MDGL), NGM Biopharmaceuticals (NGM), COMPASS Pathways (CMPS), MorphoSys (MOR), Xenon Pharmaceuticals (XENE), GH Research (GHRS), Endo International (ENDP), Keros Therapeutics (KROS), ALX Oncology (ALXO), Axsome Therapeutics (AXSM), Crinetics Pharmaceuticals (CRNX), Organogenesis (ORGO) and uniQure (QURE).
View all of MEIP's competitors.

What other stocks do shareholders of MEI Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MEI Pharma investors own include Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), OPKO Health (OPK), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE) and TherapeuticsMD (TXMD).

What is MEI Pharma's stock symbol?

MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."

Who are MEI Pharma's major shareholders?

MEI Pharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.86%), Wasatch Advisors Inc. (5.63%), Geode Capital Management LLC (1.50%), Point72 Asset Management L.P. (0.97%), Renaissance Technologies LLC (0.89%) and Millennium Management LLC (0.43%). Company insiders that own MEI Pharma stock include Brian G Drazba, Daniel P Phd Gold, Frederick W Driscoll and Thomas C Reynolds.
View institutional ownership trends for MEI Pharma.

Which institutional investors are selling MEI Pharma stock?

MEIP stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., BlackRock Inc., Goldman Sachs Group Inc., Two Sigma Advisers LP, Renaissance Technologies LLC, Millennium Management LLC, California State Teachers Retirement System, and Connor Clark & Lunn Investment Management Ltd..
View insider buying and selling activity for MEI Pharma or view top insider-selling stocks.

Which institutional investors are buying MEI Pharma stock?

MEIP stock was bought by a variety of institutional investors in the last quarter, including Sigma Planning Corp, Bank of New York Mellon Corp, SG Americas Securities LLC, Geode Capital Management LLC, Barclays PLC, GSA Capital Partners LLP, BNP Paribas Arbitrage SA, and Man Group plc. Company insiders that have bought MEI Pharma stock in the last two years include Brian G Drazba, Daniel P Phd Gold, and Thomas C Reynolds.
View insider buying and selling activity for MEI Pharma or or view top insider-buying stocks.

How do I buy shares of MEI Pharma?

Shares of MEIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MEI Pharma's stock price today?

One share of MEIP stock can currently be purchased for approximately $3.37.

How much money does MEI Pharma make?

MEI Pharma has a market capitalization of $379.87 million and generates $25.53 million in revenue each year. The company earns $-50.58 million in net income (profit) each year or ($0.66) on an earnings per share basis.

How many employees does MEI Pharma have?

MEI Pharma employs 51 workers across the globe.

What is MEI Pharma's official website?

The official website for MEI Pharma is www.meipharma.com.

Where are MEI Pharma's headquarters?

MEI Pharma is headquartered at 11455 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130.

How can I contact MEI Pharma?

MEI Pharma's mailing address is 11455 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The company can be reached via phone at (858) 369-7100, via email at [email protected], or via fax at 302-655-5049.